Lymphact
Takeda China is committed to providing innovative healthcare solutions and improving patient outcomes. The company emphasizes corporate social responsibility, sustainable development, and high-quality pharmaceutical production. It actively engages in community support, environmental protection, and employee well-being, aiming to create value for society and contribute to global health. As a global biopharmaceutical company with a history of over 240 years, Takeda focuses on patient-centric innovation across various therapeutic areas including metabolic and cardiovascular diseases, oncology, respiratory, immunology, neurology, and vaccines. It has a strong presence in China since 1994, striving to build an extraordinary employee experience and uphold a corporate culture of integrity, fairness, and perseverance.
Industries
Nr. of Employees
small (1-50)
Lymphact
No. 1-3, Lane 168, Xinjinqiao Road, Pudong New Area, Shanghai, China
Patents
Products
Oral DPP-4 inhibitor for type 2 diabetes (approved in multiple regions)
An oral dipeptidyl peptidase-4 inhibitor developed to complement diet and exercise for glycemic control in adult type 2 diabetes; evaluated in large multinational Phase III programs and long-term active-comparator trials.
Monoclonal antibody therapy for moderate-to-severe inflammatory bowel disease
A biologic monoclonal antibody therapeutic developed for induction and maintenance of response in adult patients with moderate-to-severe ulcerative colitis or Crohn's disease, including use after inadequate response to prior biologic therapy.
Oral DPP-4 inhibitor for type 2 diabetes (approved in multiple regions)
An oral dipeptidyl peptidase-4 inhibitor developed to complement diet and exercise for glycemic control in adult type 2 diabetes; evaluated in large multinational Phase III programs and long-term active-comparator trials.
Monoclonal antibody therapy for moderate-to-severe inflammatory bowel disease
A biologic monoclonal antibody therapeutic developed for induction and maintenance of response in adult patients with moderate-to-severe ulcerative colitis or Crohn's disease, including use after inadequate response to prior biologic therapy.
Services
End-to-end design and conduct of multinational clinical trials, including randomized double-blind Phase III programs and long-term active-comparator studies assessing efficacy durability and safety.
Manufacturing and distribution operations meeting GMP standards, including local importation and distribution entities to support market supply and implementation of energy-efficiency measures.
Structuring and executing co-promotion agreements with other pharmaceutical companies to leverage partner commercial networks for expanded product reach.
End-to-end design and conduct of multinational clinical trials, including randomized double-blind Phase III programs and long-term active-comparator studies assessing efficacy durability and safety.
Manufacturing and distribution operations meeting GMP standards, including local importation and distribution entities to support market supply and implementation of energy-efficiency measures.
Structuring and executing co-promotion agreements with other pharmaceutical companies to leverage partner commercial networks for expanded product reach.
Expertise Areas
- Clinical trial management (Phase I–III)
- Long-term comparative diabetes trial design and execution
- Cardiovascular outcomes and safety trial methodology
- Pharmacovigilance and clinical safety governance
Key Technologies
- DPP-4 inhibitor small-molecule therapeutics
- Fixed-dose combination oral formulation technologies
- Monoclonal antibody biologic platforms
- GMP manufacturing processes
News & Updates
Takeda and Sanofi announced a strategic cooperation to jointly promote the diabetes drug Alogliptin in China, aiming to benefit more patients with type 2 diabetes.
Clinical data from the EXAMINE trial showing that Alogliptin does not increase cardiovascular risk in high-risk type 2 diabetes patients, published in the New England Journal of Medicine.
Takeda announced its financial results for the fiscal year ending March 31, 2014, with a focus on innovation and strategic growth in global markets.
Takeda announced the appointment of Christophe Weber as COO and future CEO, emphasizing its global strategy and leadership.
Takeda was recognized for its sustainability and corporate social responsibility efforts, being included in the Dow Jones Sustainability Asia-Pacific Index for four consecutive years.
Takeda was listed in the FTSE4Good Global Index, reflecting its commitment to environmental, social, and governance standards.
Takeda and Sanofi announced a strategic cooperation to jointly promote the diabetes drug Alogliptin in China, aiming to benefit more patients with type 2 diabetes.
Clinical data from the EXAMINE trial showing that Alogliptin does not increase cardiovascular risk in high-risk type 2 diabetes patients, published in the New England Journal of Medicine.
Takeda announced its financial results for the fiscal year ending March 31, 2014, with a focus on innovation and strategic growth in global markets.
Takeda announced the appointment of Christophe Weber as COO and future CEO, emphasizing its global strategy and leadership.
Takeda was recognized for its sustainability and corporate social responsibility efforts, being included in the Dow Jones Sustainability Asia-Pacific Index for four consecutive years.
Takeda was listed in the FTSE4Good Global Index, reflecting its commitment to environmental, social, and governance standards.